Why Eli Lilly's Successful Alzheimer's Disease Study Was So Disappointing

Attention for Eli Lilly (NYSE: LLY) has been blowing up since the company announced success for its experimental new Alzheimer's disease drug. Unfortunately, the results strongly suggest that Eli Lilly and Biogen (NASDAQ: BIIB) have a lot more work to do.

How can a clinical trial that succeeded also foreshadow a slow-motion trainwreck? Strap in for some nuance.

Image source: Getty Images.

Continue reading

Source Fool.com